Article

Development of Transdermal Delivery System of Vildagliptin and Its Comparison with Oral Therapy

Anroop B Nair1, Rachna Kumria2★, Bandar E Al-Dhubiab1, Mahesh Attimarad1, Sree Harsha1★ Corresponding author

  1. 1Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.
  2. 2Swift School of Pharmacy, Village-Ghaggar Sarai, Rajpura, Patiala, Punjab, India.

CORRESPONDENCE

Rachna Kumria

Swift School of Pharmacy, Village-Ghaggar Sarai, Rajpura, Patiala, Punjab, India.

anair@kfu.edu.sa

Received: 03-12-2014; Revised: 22-06-2015; Accepted: 19-07-2015.

Volume 50, Issue 1 · pp. 130–137 · PUBLISHED 2016 · DOI: anair@kfu.edu.sa

View on IJPER original site ↗

ABSTRACT

Purpose: The long term oral therapy of vildagliptin is associated with potential hepatotoxicity and low patient compliance. This study aims at development of a drug in adhesive transdermal patch system of vildagliptin using pressure sensitive acrylic polymers and compare the pharmacokinetics with oral therapy.Methods: The prospective of different chemical enhancers in improving the transport of vildagliptin was assessed ex vivo. In vivo permeation studies in rats were performed using patch system contain sodium lauryl sulfate as enhancer. Results: Drug solubility varied among adhesive bases tested and maximum value (15% w/w) observed with Duro-Tak 87-2510. Incorporation of chemical agents significantly improved the permeation of vildagliptin, but not to the same extent. The highest flux value of vildagliptin was obtained by the addition of sodium lauryl sulfate (22.96 ± 3.58 µg/cm2/h; P<0.0001), which is ~4 folds higher as compared to control. Pharmacokinetic profiles of vildagliptin were different for transdermal and oral delivery with significantly high bioavailability by transdermal delivery. The AUC0-α in transdermal delivery (1018.43 ± 79.56 ng.h/mL) was ~14 folds higher (P<0.0001) as compared to oral administration. Conclusion: The current study concludes that the fabricated drug in adhesive transdermal system could be employed for the effective delivery of vildagliptin.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    • DOIanair@kfu.edu.sa

    SELECT FORMAT

    Nair, A. B., Kumria, R., Al-Dhubiab, B. E., Attimarad, M., & Harsha, S. (2016). Development of Transdermal Delivery System of Vildagliptin and Its Comparison with Oral Therapy. Indian Journal of Pharmaceutical Education and Research, 50(1), 130–137. https://doi.org/anair@kfu.edu.sa